admin

Industry veterans Paul Peter Tak and Eric Meldrum join Citryll’s Board

We warmly welcome Paul Peter and Eric and are incredibly honoured to have them on the Board of Citryll. Their impressive and complementary track records in drug discovery and development in pharma, biotech and academia will add significant value…

Senior Technician(s) Immunology, Cell Biology & Pharmacology

You will work in a small team of PhD scientists and senior research associates, and participate in development and validation of cellular, immunochemical and biochemical assays
, pharmacological in vitro studies with CIT-013 and patient blood samples …

Citryll completes € 18.5 M fundraise to develop CIT-013, an antibody targeting Neutrophil Extracellular Traps

Citryll announced it closed a total fundraise of € 18.5 million, led by Seventure (including their Health for Life Capital II fund), co-led by BioGeneration Ventures (BGV) with existing investors BOM Brabant Ventures, BrightGene and ModiQuest contributing…

Senior Scientist Immunology

As Senior Scientist Immunology you will be working in collaboration with Citryll team members in Oss and world-class external partners including CROs, academics and pharma and accelerate the progress of our therapeutic programs.

Antibodies clamp down on NET nucleosomes

In the current issue of CMI, Chirivi et al. describe the isolation and characterization of a monoclonal antibody that may find applications in numerous inflammatory conditions. This new antibody, called tACPA, inhibits the completion …

Landmark paper on Citryll’s NET inhibitor programme published in Nature’s Cellular and Molecular Immunology

Oss, The Netherlands, March 20, 2020 —www.citryll.com Citryll announced today that a landmark scientific paper has been published in Nature’s Cellular and Molecular Immunology journal, to be found at …

Therapeutic ACPA inhibits NET formation: a potential therapy for neutrophil-mediated inflammatory diseases

Excessive release of neutrophil extracellular traps (NETs) is associated with disease severity and contributes to tissue injury, followed
by severe organ damage …

Citryll moves to new premises at Pivot Park in Oss, The Netherlands

Oss, The Netherlands, October 21, 2019 —www.citryll.com Citryll announced today that it
has occupied new office and lab space at the Pivot Park in Oss the Netherlands.

Citryll collaborates with leading NET researcher Dr. Markus Hoffmann

Oss, The Netherlands, Erlangen, Germany September 18, 2019 —http://www.citryll.com/ announced today that it has established a collaboration with Dr. Markus Hoffmann of the Department of Medicine 3, Friedrich Alexander University of …

Citryll and Lonza Enter Into Partnership to Manufacture NETosis Inhibiting Antibody CIT-013

Oss, The Netherlands and Basel, Switzerland, 9 September 2019 – The Netherlands-based biotech Citryll and CDMO Lonza announced a partnership to develop and manufacture Citryll’s tACPA therapeutic antibody CIT-013.